(Q34272145)

1 August 2017

1 reference

title

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. (English)

1 reference

1 August 2017

Kozlowski A

1

1 reference

PubMed ID

11390000

1 August 2017

Harris JM

series ordinal

2

1 reference

PubMed ID

11390000

1 August 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Journal of Controlled Release

1 August 2017

1 reference

1 August 2017

72

1 reference

1 August 2017

1-3

1 reference

1 August 2017

217-224

1 reference

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

A branched monomethoxypoly(ethylene glycol) for protein modification

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

Effects of Coupling Chemistry on the Activity of Poly(ethylene glycol)-Modified Alkaline Phosphatase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

LABORATORY SYNTHESIS OF POLYETHYLENE GLYCOL DERIVATIVES

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

Characterization and stability of N-terminally PEGylated rhG-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

Preparation of characterization of poly(ethylene glycol) vinyl sulfone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

Therapeutic antibody fragments with prolonged in vivo half-lives

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900277-2

7 January 2021

10.1016/S0168-3659(01)00277-2

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11390000